

TG THERAPEUTICS, INC.  
Form 8-K  
August 08, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 8, 2016

TG Therapeutics, Inc.  
(Exact Name of Registrant as Specified in Charter)

Delaware                                      001-32639                                      36-3898269  
(State or Other Jurisdiction (Commission File Number) (IRS Employer Identification No.)  
of Incorporation)

2 Gansevoort Street, 9th Floor  
New York, New York 10014  
(Address of Principal Executive Offices)

(212) 554-4484  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act.

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.



Item 2.02. Results of Operations and Financial Condition.

On August 8, 2016, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the second quarter ended June 30, 2016. TG also announced that on Monday, August 8, 2016 at 8:30am ET, TG would host an investor conference call during which the Company would provide a brief overview of its second quarter financial results and provide a business outlook for the remainder of 2016. A copy of such press release is being furnished as Exhibit 99.1.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1

Press release issued by TG Therapeutics, Inc., dated August 8, 2016.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.  
(Registrant)

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer

Date: August 8, 2016



INDEX TO EXHIBITS

Exhibit Number	Description
99.1	Press release issued by TG Therapeutics, Inc., dated August 8, 2016.